Clinical Oncology Next Generation Sequencing Market: as FDA companion diagnostic approvals for liquid biopsy comprehensive genomic profiling expand beyond 25 indications, blood-based tumour testing achieves clinical equivalence with tissue biopsy in an expanding range of solid tumour types, so reimbursement variability across payer types and China sequencing instrument trade restrictions become the primary constraints on global testing volume acceleration rather than the clinical evidence base.

The global clinical oncology next generation sequencing market size was USD 4.86 Billion in 2025 and is expected to register a revenue CAGR of 13.8% during the forecast period. Market revenue growth is driven by factors such as liquid biopsy companion diagnostic indication expansion establishing blood-based comprehensive genomic profiling as a multi-tumour standard, clinical consumables revenue acceleration at the leading NGS instrument platform, and as well as minimal residual disease monitoring category emergence creating a new recurring post-treatment testing channel. The first driving factor is Guardant Health’s Guardant360 CDx reaching its 25th FDA-approved companion diagnostic indication in January 2026 with approval for BRAF V600E-mutant metastatic colorectal cancer supported by phase 3 BREAKWATER trial data, and subsequently receiving FDA approval as a companion diagnostic for HERNEXEOS in HER2-mutant non-small cell lung cancer, establishing liquid biopsy comprehensive genomic profiling as a clinically validated and broadly reimbursed alternative to tissue biopsy across an expanding range of solid tumour indications. The second driving factor is Illumina reporting full-year fiscal 2025 revenue of USD 4.34 Billion with clinical consumables revenue accelerating to 20% year-over-year growth in Q4 2025 when excluding China, demonstrating sustained underlying clinical oncology NGS testing volume growth at hospital and reference laboratory customers globally independent of the China trade policy headwind. The third driving factor is the expanding evidence base for ctDNA-based minimal residual disease monitoring following curative-intent cancer treatment, with Guardant Health, Natera, and Exact Sciences all investing in prospective clinical trials demonstrating MRD monitoring clinical utility for treatment guidance and recurrence detection across colorectal, breast, and lung cancer patient populations. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way FDA companion diagnostic indication approvals create mandatory testing requirements that generate recurring comprehensive genomic profiling test orders at each enrolled patient without requiring independent clinical utility evidence at each ordering occasion, which allows each new CDx approval to unlock a new recurring testing channel above the existing ordered-at-physician-discretion testing volume. Once a targeted oncology therapy receives FDA approval with a mandatory companion diagnostic requirement, every patient being evaluated for that therapy must have a qualifying comprehensive genomic profiling test performed before treatment initiation, so the commercial addressability of liquid biopsy comprehensive genomic profiling compounds directly with the clinical adoption rate of each new FDA-approved targeted therapy requiring Guardant360 CDx testing. As a result, demand and revenue share are concentrating around the platforms with the largest approved companion diagnostic indication portfolios and the broadest payer coverage for those indications, and the forecast tilts toward these mandated CGP platforms rather than laboratory-developed tests without FDA companion diagnostic approval. For instance, in September 2025, the FDA approved Guardant360 CDx as a companion diagnostic for imlunestrant in ESR1-mutated advanced breast cancer, one of five separate Guardant360 CDx indication expansions that reshaped the liquid biopsy CGP competitive landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the rapid expansion of Guardant360 CDx companion diagnostic indications through FDA approval, which each create a mandatory liquid biopsy testing requirement at the point of treatment selection for patients enrolled in the approved targeted therapy. Companion diagnostic testing works commercially because every patient evaluated for an FDA-approved targeted oncology therapy requiring a CDx must have a qualifying test performed, making the test a mandated step in the treatment workflow rather than an optional clinical utility decision, and Guardant360 CDx requiring only two tubes of blood and yielding actionable results in five days provides a faster, less invasive alternative to tissue biopsy for the comprehensive genomic profiling required to identify biomarker-eligible patients. Guardant Health received FDA approval for Guardant360 CDx as a companion diagnostic for encorafenib plus cetuximab and chemotherapy in BRAF V600E-mutant metastatic colorectal cancer in January 2026, marking the 25th companion diagnostic indication and the first liquid biopsy CDx for BRAF-mutant CRC, supported by phase 3 BREAKWATER trial data demonstrating significantly improved outcomes versus standard of care. Guardant360 CDx subsequently received FDA approval for HERNEXEOS in HER2-mutant advanced non-small cell lung cancer and for imlunestrant in ESR1-mutated advanced breast cancer, with the ESR1 indication marking the test’s sixth total indication and second in breast cancer and demonstrating that liquid biopsy-based companion diagnostics are now covering multiple tumour types and molecular targets simultaneously. The effect on the market is that 25-plus companion diagnostic indications covering colorectal, lung, breast, and other solid tumour types creates a recurring testing demand stream that is mandated by FDA therapy approval conditions, generating CGP test orders independently of individual physician clinical utility decisions and creating a recurring revenue base that compounds with each new therapy approval requiring Guardant360 CDx. These are some of the key factors driving revenue growth of the market.

The second driver is the confirmed acceleration in clinical oncology NGS consumables revenue growth at Illumina, the dominant global NGS instrument and reagent platform provider, which demonstrates that hospital and reference laboratory customers are increasing sequencing run volumes across existing installed instrument bases rather than requiring new instrument capital placements to drive consumables revenue acceleration. Consumables acceleration works commercially because each installed NGS instrument generates recurring reagent cartridge and consumable revenue as testing volumes grow, so the 50,000-plus instrument placements at clinical laboratory customers globally represent a compounding consumables revenue base that grows as cancer testing volume expands without requiring equivalent capital placement investment. Illumina reported full-year fiscal 2025 revenue of USD 4.34 Billion, flat year-over-year, but confirmed an acceleration in clinical sequencing consumables sales over the course of 2025, with Q4 2025 clinical consumables revenue growing 20% year-over-year in geographic regions excluding China. Illumina completed integration of its latest XLEAP-SBS chemistry into all reagents for NextSeq 1000 and NextSeq 2000 instruments in 2024, and expanded its oncology menu for NovaSeq X Series customers by offering the high-throughput version of TruSight Oncology 500 alongside the latest TruSight Oncology 500 ctDNA v2 distributed liquid biopsy research assay. Illumina also launched DRAGEN version 4.3 bioinformatics analysis software in 2024 and introduced TruSight Oncology Comprehensive Panel version 2, designed to identify a broader range of clinically relevant genomic alterations across solid tumour types. The effect on the market is that 20% consumables growth excluding China at the dominant NGS instrument platform confirms that underlying clinical oncology sequencing demand is accelerating in all major markets outside China, so the 13.8% CAGR trajectory is supported by both the CDx mandate demand channel and the discretionary CGP testing demand channel growing simultaneously. These are some of the key factors driving revenue growth of the market.

Guardant360 CDx is broadly covered by Medicare and many private payers for its FDA-approved companion diagnostic indications, with the test requiring only two tubes of blood and yielding actionable results in five days. At 25 FDA-approved companion diagnostic indications across colorectal, lung, and breast cancer by January 2026, liquid biopsy comprehensive genomic profiling has achieved the multi-tumour indication breadth that establishes it as a clinically equivalent alternative to tissue biopsy in the indications where both testing modalities provide guideline-concordant treatment eligibility information, shifting the clinical default from tissue-first to blood-first in those indication-specific workflows.

The third driver is the emergence of ctDNA-based minimal residual disease monitoring as a clinically validated and commercially expanding post-treatment testing category that generates recurring test orders per cancer patient throughout the 2 to 5 year post-treatment surveillance period following curative-intent resection or systemic treatment. MRD monitoring works commercially because each patient who completes curative-intent cancer treatment becomes a recurring testing customer for multiple years of post-treatment surveillance, generating a durable recurring revenue stream per patient that is structurally separate from and additive to the treatment-selection comprehensive genomic profiling revenue generated at initial diagnosis. Natera’s Signatera platform has established the strongest commercial MRD monitoring evidence base, with published prospective data in colorectal cancer demonstrating that ctDNA MRD positivity after curative-intent resection predicts clinical recurrence with a median lead time of 8 months before imaging-detectable relapse, supporting the clinical utility of serial ctDNA monitoring for early recurrence detection. CMS issued a national coverage determination for Signatera ctDNA monitoring in colorectal cancer post-surgical surveillance in March 2026, providing the first Medicare reimbursement framework for ctDNA MRD testing as a covered clinical service and establishing the reimbursement precedent that other MRD platforms including Guardant Reveal and Exact Sciences Oncodetect are targeting for their own indication-specific Medicare coverage determinations. The effect on the market is that MRD monitoring creates a second structural growth layer above initial diagnosis CGP testing, adding recurring post-treatment testing volume per patient that extends the clinical oncology NGS revenue opportunity well beyond the initial treatment selection episode, which is why the 13.8% CAGR forecast substantially exceeds the underlying cancer incidence growth rate in the target population. These are some of the key factors driving revenue growth of the market.

However, the clinical oncology NGS market faces adoption constraints from China trade policy impacts and reimbursement variability. Because Illumina confirmed Q4 2025 China clinical consumables revenue declined 30% year-over-year due to China Ministry of Commerce trade policy actions, with FY2025 guidance explicitly excluding this impact and the policy representing a near-term headwind of approximately USD 150 to 200 Million in annualised China revenue at the dominant sequencing platform provider, the trade restriction removes one of the largest addressable cancer testing market growth opportunities from the near-term NGS market forecast. Reimbursement variability is a second constraint, because while Guardant360 CDx is broadly covered by Medicare and many private payers for its 25 FDA-approved companion diagnostic indications, coverage policies for minimal residual disease monitoring applications, hereditary cancer risk testing, and comprehensive genomic profiling in tumour types without FDA companion diagnostic approval remain inconsistently established across the broader payer landscape, so the commercially realisable testing volume is below the clinically indicated testing volume in multiple cancer type and indication combinations. Capital and infrastructure cost is the third constraint, since the NovaSeq X Series and bioinformatics pipeline infrastructure required for clinical laboratory-scale comprehensive genomic profiling panel processing represents a capital investment level that constrains adoption among community cancer centres and smaller hospital systems relative to large academic medical centres and commercial reference laboratories with dedicated molecular oncology infrastructure already built to scale. These factors substantially limit clinical oncology next generation sequencing market growth over the forecast period.

Based on sample type, the global clinical oncology NGS market is segmented into tissue biopsy, liquid biopsy, and bone marrow or hematologic sample testing. Tissue biopsy currently holds the largest revenue share, reflecting the established clinical workflow for FFPE tissue-based comprehensive genomic profiling including Foundation Medicine’s FoundationOne CDx. Liquid biopsy is expected to register the most rapid revenue growth rate in the global clinical oncology NGS market over the forecast period, driven directly by Guardant360 CDx reaching 25 FDA-approved companion diagnostic indications by January 2026, requiring only two tubes of blood and delivering results within five days, offering a faster, less invasive alternative that is particularly valuable when tissue samples are inadequate for testing, which is why the physician default is shifting from tissue-first to blood-first comprehensive genomic profiling in colorectal, lung, and breast cancer indications where both modalities have equivalent FDA companion diagnostic approval.

Based on regional analysis, the clinical oncology NGS market in North America accounted for largest revenue share in 2025. The United States drives the regional position through the concentrated presence of Illumina’s San Diego headquarters and Guardant Health’s Redwood City, California headquarters, combined with the FDA’s active companion diagnostic approval pathway that has enabled Guardant360 CDx to reach 25 indications by January 2026 and broad Medicare and commercial payer coverage for FDA-approved comprehensive genomic profiling tests. Illumina confirmed at ASCO 2024 the presentation of 14 total research abstracts, reflecting the concentration of US-based academic and clinical oncology NGS research activity anchoring North American market leadership. The concentration of major commercial reference laboratory NGS operations including Guardant Health’s liquid biopsy laboratory in Palo Alto, Foundation Medicine’s Cambridge laboratory, and Natera’s Austin laboratory also means that clinical oncology NGS test volume scales from North American reference laboratory infrastructure first before equivalent testing capacity is established in European or Asian markets.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and Italy represent significant national clinical oncology NGS markets within Europe, with TruSight Oncology 500 panel adoption documented at academic cancer centres across Germany, the UK, and the Netherlands under WHO 2021 CNS tumour classification frameworks requiring molecular tumour characterisation. The European IVD Regulation framework creates distinct approval timelines for companion diagnostic assays in Europe relative to the US FDA pathway, meaning Guardant360 CDx’s 25 US indications do not translate directly to equivalent European CE-marked companion diagnostic coverage, extending the European liquid biopsy CGP reimbursement pathway timeline by 12 to 24 months relative to US approval dates. Reimbursement through national health technology assessment bodies in Germany, France, and the UK evaluates companion diagnostic clinical utility on multi-year evidence dossier review timelines, creating a structural delay between US FDA approval and European national health system coverage for new CGP indications.

The market in Asia Pacific is expected to register a moderate revenue growth rate over the forecast period in the near term, constrained by the China trade policy headwind affecting Illumina’s clinical consumables revenue, which Illumina confirmed declined 30% year-over-year in Q4 2025. Japan, South Korea, and Australia represent the largest clinical oncology NGS markets within Asia Pacific outside China, with well-developed oncology centre NGS testing infrastructure and national health insurance coverage frameworks for approved targeted oncology therapies that require companion diagnostic testing, supporting a durable underlying CGP test volume base. India’s expanding oncology centre infrastructure and growing private hospital cancer diagnostic investment represent the fastest-growing clinical oncology NGS market within Asia Pacific outside the China trade policy impact zone, with domestic NGS panel laboratory capacity expanding in Bengaluru, Hyderabad, and Mumbai.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the largest national clinical oncology NGS markets in the region, concentrated in private oncology hospital and diagnostic laboratory settings in major urban centres. The indirect effects of Iran-US sanctions on South American freight routes have maintained elevated import costs for NGS sequencing reagent consumables and library preparation kits entering Brazilian and Mexican laboratory distribution networks through 2026, contributing to higher per-test costs that limit the addressable market for comprehensive genomic profiling to the private healthcare sector.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the United Arab Emirates represent the primary clinical oncology NGS markets within the GCC, supported by government investment in comprehensive cancer centre diagnostic infrastructure including molecular pathology capabilities at major GCC public hospital cancer centres. South Africa is the most established clinical oncology NGS market on the African continent, with NGS-based cancer diagnostic testing available at private oncology centres in Cape Town and Johannesburg, while Sub-Saharan Africa represents a largely underpenetrated addressable market where basic molecular oncology diagnostic infrastructure is still being developed.